Distinct genetic alteration profiles of acute myeloid leukemia between Caucasian and Eastern Asian population-Reference-Cited by-同舟云学术

Distinct genetic alteration profiles of acute myeloid leukemia between Caucasian and Eastern Asian population

Published:2018-02-10 Issue:1 Volume:11 Page:
ISSN:1756-8722
Container-title:Journal of Hematology & Oncology
language:en
Short-container-title:J Hematol Oncol

Author:

Wei Hui,Wang Ying,Zhou Chunlin,Lin Dong,Liu Bingcheng,Liu Kaiqi,Qiu Shaowei,Gong Benfa,Li Yan,Zhang Guangji,Wei Shuning,Gong Xiaoyuan,Liu Yuntao,Zhao Xingli,Gu Runxia,Mi Yingchang,Wang Jianxiang

Funder

State Key Program of National Natural Science Foundation of China

Foundation for Innovative Research Groups of the National Natural Science Foundation of China

National Natural Science Foundation of China

CAMS Innovation Fund for Medical Sciences

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Molecular Biology,Hematology

Link

http://link.springer.com/content/pdf/10.1186/s13045-018-0566-8.pdf

Reference13 articles.

1. Lee JH, Joo YD, Kim H, Bae SH, Kim MK, Zang DY, Lee JL, Lee GW, Lee JH, ParkJH, Kim DY, Lee WS, Ryoo HM, Hyun MS, Kim HJ, Min YJ, Jang YE, Lee KH; Cooperative Study Group A for Hematology. A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia. Blood. 2011;118(14):3832-3841.

2. Ohtake S, Miyawaki S, Fujita H, Kiyoi H, Shinagawa K, Usui N, Okumura H, Miyamura K, Nakaseko C, Miyazaki Y, Fujieda A, Nagai T, Yamane T, Taniwaki M, Takahashi M, Yagasaki F, Kimura Y, Asou N, Sakamaki H, Handa H, Honda S, Ohnishi K, Naoe T, Ohno R. Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study. Blood. 2011;117(8):2358–65.

3. Jin J, Wang JX, Chen FF, Wu DP, Hu J, Zhou JF, Hu JD, Wang JM, Li JY, Huang XJ, Ma J, Ji CY, Xu XP, Yu K, Ren HY, Zhou YH, Tong Y, Lou YJ, Ni WM, Tong HY, Wang HF, Mi YC, Du X, Chen BA, Shen Y, Chen Z, Chen SJ. Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: amulticentre, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2013;14(7):599–608.

4. Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM, Racevskis J, Dewald GW, Ketterling RP, Bennett JM, Rowe JM, Lazarus HM, Tallman MS. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009;361(13):1249–59.

5. Burnett AK, Russell NH, Hills RK, Hunter AE, Kjeldsen L, Yin J, Gibson BE, Wheatley K, Milligan D. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. J Clin Oncol. 2013;31(27):3360–8.

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular and clinical aspects relevant for counseling individuals with clonal hematopoiesis of indeterminate potential;Frontiers in Oncology;2023-12-15

3. Immunophenotype distinctions of CEBPA mutation subtypes in acute myeloid leukemia;International Journal of Laboratory Hematology;2023-06-19

4. FDA Analysis of Ineligibility for Acute Myeloid Leukemia Clinical Trials by Race and Ethnicity;Clinical Lymphoma Myeloma and Leukemia;2023-06

5. Heterogeneity analysis of the CEBPAdm AML based on bZIP region mutations;Blood Science;2023-03-06